Filing Analysis
Streamex Corp. filed an 8-K to furnish its second quarter 2026 financial results and earnings presentation. The filing is a routine disclosure of quarterly results and does not contain adverse material news.
📋 Key Facts
- Company issued an earnings release for the second quarter ended June 30, 2026, on August 14, 2026.
- Company hosted a conference call on August 17, 2026, to discuss financial results and provide a business update.
- An earnings presentation was made available on the company's website on August 17, 2026.
Streamex Corp. announced the resignation of Shawn Matthews from the Board of Directors and all associated committees, effective July 29, 2026.
📋 Key Facts
- Shawn Matthews resigned from the Board and all committees on July 29, 2026.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
- A potential candidate has been identified to fill the vacancy but no formal appointment has been made as of the filing date.
Streamex Corp. has dismissed CBIZ CPAs P.C. and appointed EisnerAmper LLP as its new independent registered public accounting firm, effective July 8, 2026. While the company claims no disagreements regarding audit opinions, it disclosed a reportable event involving material weaknesses in internal controls over financial reporting.
🚩 Red Flags
- Auditor change combined with the disclosure of reportable events related to material weaknesses in internal controls.
- Material weakness in stock-based compensation reporting (risk of future restatements).
- Ineffective review processes over period-end financial disclosures and business combinations.
📋 Key Facts
- Dismissal of CBIZ CPAs P.C. approved by the Audit Committee on July 8, 2026.
- Appointment of EisnerAmper LLP as the successor independent auditor.
- The company reported a 'reportable event' regarding material weaknesses in internal control over financial reporting (ICFR) identified in the FY2025 10-K filed March 31, 2026.
- Specific material weaknesses include: inadequate stock-based compensation recording, ineffective period-end review processes, inadequate segregation of duties, and ineffective review controls over business combinations.
Streamex Corp. held its 2025 annual meeting of stockholders on December 30, 2025, where shareholders approved several key items including the election of two directors and an amendment to the company's long-term incentive plan.
🚩 Red Flags
- Increase in authorized shares under the Incentive Plan (potential future dilution).
📋 Key Facts
- Annual Meeting held on December 30, 2025, with a quorum representing 81.21% of total outstanding shares (148,654,805 shares).
- Stockholders approved the Fourth Amendment to the 2023 Long-Term Incentive Plan, increasing authorized shares under the plan by 22,494,324 to a total of 37,230,130.
- Morgan Lekstrom and Karl Henry McPhie were elected to the Board of Directors (Class I) with over 99% support each.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved a three-year frequency for advisory votes on executive compensation.
Streamex Corp. has completed a second tranche of a secured convertible debenture issuance to Yorkville (YA II PN, LTD) for $25 million in principal. The transaction includes highly dilutive conversion terms and significant interest rate escalations upon default.
🚩 Red Flags
- Highly dilutive 'death spiral' style conversion mechanism (conversion price linked to VWAP with a downward reset).
- Significant interest rate step-up from 4% to 18% in the event of default.
- Multiple amendments and tranches of debt issuance within a short period (July, August, October, November, December 2025), indicating potential liquidity struggles.
- The conversion price floor ($4.00) is significantly higher than current market context might suggest for micro-caps in distress, but the VWAP linkage remains highly dilutive.
📋 Key Facts
- Issued the second tranche of Convertible Debentures on December 17, 2025.
- Principal amount: $25,000,000; Gross proceeds to Company: approximately $24,000,000 (96.0% of principal).
- Maturity date: December 17, 2027.
- Interest rate: 4.00% per annum, increasing to 18.00% per annum upon an event of default.
- Conversion price: The lower of $6.016 or a VWAP-based formula (including a downward reset) or 97.0% of the lowest daily VWAP over three days, subject to a $4.00 floor.
- Investor ownership cap: Yorkville is limited to owning 4.99% of outstanding Common Stock upon conversion.
Streamex Corp. entered into a Share Purchase Agreement to acquire a 9.9% equity interest in Empress Royalty Corp. through an all-stock transaction. The deal provides Streamex with exposure to gold and silver royalty assets as part of its strategic pivot toward commodity-linked infrastructure.
🚩 Red Flags
- All-stock transaction increases potential dilution for existing shareholders via the issuance of 2.4M+ new shares.
📋 Key Facts
- Acquisition date: December 11, 2025
- Asset acquired: 12,671,297 shares (9.9% equity interest) of Empress Royalty Corp.
- Consideration paid: 2,443,750 shares of Streamex Corp. common stock
- Implied price per STEX share: US$5.00
- Aggregate transaction value: US$12,218,751.00 (C$17,106,251.62)
- Purchaser: Terra Capital Natural Resources Fund Pty Ltd.
Streamex Corp. underwent a massive board overhaul involving the immediate resignation of three directors and several key executive employment agreements. The filing also details a transition to a classified board structure following a prior share purchase agreement.
🚩 Red Flags
- Massive simultaneous resignation of three board members (including Audit Committee leadership) is highly unusual and often signals internal friction or control shifts.
- Immediate departure of Steven Abelman, who served as Chairman of the Audit Committee.
- Significant new compensation/equity packages for CEO, CFO, and Chairman are pending stockholder approval, indicating potential dilution risk.
📋 Key Facts
- Three directors—Steven Abelman, Christopher Baer, and Anthony Amato—resigned effective November 18, 2025.
- Kevin Gopaul appointed as an independent director (Class II) and member of Audit, Compensation, and Nominating committees.
- CEO Karl Henry McPhie entered a new employment agreement with a $225,000 base salary and potential equity grants subject to stockholder approval.
- CFO Ferdinand Groenewald entered an employment agreement with a $225,000 base salary and performance-based incentives.
- Chairman Morgan Lekstrom entered a new Chairman Agreement including a $99,000 annual retainer for his role as Chairman/Compensation Chair.
- The company filed the Eleventh Amendment to its Certificate of Incorporation to implement a classified Board structure (three classes).
Streamex Corp. has completed the first closing of a $25 million tranche of a secured convertible debenture with Yorkville (YA II PN, LTD). The deal includes highly dilutive conversion terms and significant security interests over company assets.
🚩 Red Flags
- Highly dilutive conversion mechanism (97% of lowest 3-day VWAP) creates significant downward pressure on stock price.
- High default interest rate (18.00%) increases financial distress risk if covenants are breached.
- Significant asset encumbrance via US and Canadian Guaranty and Security Agreements.
- The debt is part of a larger $100,000,000 potential facility, indicating heavy reliance on external financing.
📋 Key Facts
- Issued First Convertible Debenture principal amount of $25,000,000 to Yorkville on November 4, 2025.
- Gross proceeds received: approximately $24,000,000 (96.0% of principal).
- Maturity date: November 4, 2027.
- Interest rate: 4.00% per annum, increasing to 18.00% upon event of default.
- Conversion price: The lower of $6.016 or 125% of the VWAP (with a downward reset) OR 97.0% of the lowest daily VWAP over three days, subject to a $4.00 floor.
- Security: US and Canadian Guaranty and Security Agreements were executed, providing collateral for the debt.
Streamex Corp. (formerly BioSig Technologies, Inc.) has successfully completed the acquisition of Streamex Exchange Corporation following a stockholder vote. The transaction involved the issuance of approximately 109 million shares of common stock and one share of Super Voting Preferred Stock.
🚩 Red Flags
- Significant dilution: The issuance of ~109 million new shares represents a massive expansion of the share float.
- Super Voting Preferred Stock: Issuance of super-voting stock typically concentrates control in specific hands (likely the sellers/insiders), reducing the voting power of minority shareholders.
📋 Key Facts
- Stockholders approved 'Proposal 1' (the Acquisition Proposal) on November 4, 2025.
- The acquisition involves the issuance of ~109,070,079 shares of common stock and one share of Super Voting Preferred Stock.
- The transaction is based on a Share Purchase Agreement dated May 23, 2025 (as amended).
- Voting results: 16,386,371 For; 267,215 Against; 27,673 Abstain.
- The company has changed its name from BioSig Technologies, Inc. to Streamex Corp.
Streamex Corp. announced that Nasdaq has granted formal approval for the continued listing of its common stock on The Nasdaq Capital Market. Additionally, the company scheduled a special meeting of stockholders for November 4, 2025, to vote on 'Proposal 1 – the Acquisition Proposal.'
🚩 Red Flags
- The need for a special meeting to reconvene an acquisition proposal suggests previous voting delays or failure to reach a quorum/threshold in prior attempts.
- The company is operating under a recent name change (f./k/a BioSig Technologies, Inc.), which can sometimes indicate corporate restructuring or distress.
📋 Key Facts
- Nasdaq has approved the continued listing of STEX (formerly BioSig Technologies, Inc.).
- A special meeting of stockholders is scheduled for November 4, 2025, at 3:00 p.m. ET.
- The purpose of the meeting is to reconvene a vote on 'Proposal 1 – the Acquisition Proposal'.
- The meeting will be held via webcast.
Streamex Corp. entered into a Second Amendment to its Secured Convertible Debenture Purchase Agreement with Yorkville, involving the issuance of up to $25 million in new convertible debentures. The deal includes highly dilutive conversion terms and requires significant collateralization of company assets.
🚩 Red Flags
- Highly dilutive 'death spiral' style conversion features (97% of lowest VWAP).
- Significant increase in interest rate (from 4% to 18%) upon default.
- First priority security interest granted over substantially all company assets.
- Requirement for Nasdaq approval to maintain listing/designation, indicating potential delisting risk or compliance pressure.
📋 Key Facts
- Amendment No. 2 to Secured Convertible Debenture Purchase Agreement signed October 28, 2025.
- Issuance of a 'First Convertible Debenture' in the principal amount of $25,000,000.
- Mandates $25.1 million in aggregate proceeds ($12.6M at First Closing, $12.5M at Second Closing) be used to purchase Allocated Vaulted Gold Bullion as collateral.
- Interest rate is 4.00% per annum, jumping to 18.00% upon event of default.
- Conversion price: Lower of (i) 125% of the prior day's VWAP or (ii) 97.0% of the lowest daily VWAP during the three trading days preceding conversion, subject to a $4.00 floor.
- The debt is secured by a first priority security interest in substantially all existing and future assets of the Company and affiliates.
BioSig Technologies, Inc. is undergoing a corporate rebranding, changing its name to Streamex Corp. and updating its ticker symbol from BSGM to STEX on the Nasdaq Stock Market.
📋 Key Facts
- Company name change: BioSig Technologies, Inc. $\rightarrow$ Streamex Corp.
- Ticker symbol change: BSGM $\rightarrow$ STEX
- Effective date for ticker change: Before market open on September 12, 2025
- The CUSIP number remains unchanged
- Existing stock certificates remain valid and will be updated in due course
BioSig Technologies entered into a three-year exclusive strategic partnership with Monetary Metals & Co. to develop and distribute blockchain-based tokenized yield products derived from precious-metal leases and bond programs.
🚩 Red Flags
- High performance dependency: Exclusivity is contingent upon meeting specific quarterly supply and net yield thresholds.
- Complexity risk: The business model relies on the intersection of blockchain technology, precious metal leasing, and complex regulatory compliance (Prohibited Persons/Restricted Nations).
📋 Key Facts
- Agreement commenced on September 8, 2025, for an initial term of three years with automatic one-year renewals.
- Exclusivity clause: MM cannot partner with others to tokenize yield; BioSig cannot partner with others to tokenize precious-metal lease yields (subject to performance conditions).
- Performance condition: BioSig must supply at least 10% of total leased ounces that meet specific insurance, net yield (>3% p.a.), and compliance standards ('Passing Leases').
- Revenue model: MM provides discounted fees/rebates on gold purchases (0.20% to 0.75%) and a quarterly revenue share on supplied gold (0.35% to 0.50%).
- Intellectual Property: BioSig owns IP related to tokenized yield products; MM retains IP for lease/bond products.
BioSig Technologies held a special meeting where stockholders approved several major proposals, including significant increases to authorized share counts and the issuance of shares related to convertible debentures. The company also approved an amendment to its long-term incentive plan and a move toward a classified board structure.
🚩 Red Flags
- Massive increase in authorized share capital (from 200M to 500M), indicating significant potential dilution.
- Heavy reliance on Yorkville for financing via convertible debentures and a Standby Equity Purchase Agreement (SEPA).
- Approval of SEPA allows the company to issue up to 19.99% or more of outstanding stock, a common mechanism in micro-cap death spirals.
- The company is undergoing significant structural changes including board classification and massive equity issuance.
📋 Key Facts
- Stockholders approved increasing authorized common stock from 200,000,000 to 500,000,000 shares (Ninth Certificate of Amendment).
- Approved the issuance of shares underlying convertible debentures to YA II PN, Ltd. ('Yorkville').
- Approved a Standby Equity Purchase Agreement (SEPA) with Yorkville allowing for potential issuance of 19.99% or more of outstanding common stock.
- Increased total shares authorized under the 2023 Long-Term Incentive Plan by 10,359,211 to a total of 14,735,806 shares.
- Approved an amendment to classify the Board of Directors into three classes with staggered three-year terms.
- Proposal 1 (issuance of ~109M shares related to Streamex acquisition) was adjourned pending Nasdaq approval; reconvenes Sept 26, 2025.
BioSig Technologies, Inc. completed a public offering of 3,852,149 shares at $3.90 per share, raising approximately $15.02 million in gross proceeds. The company intends to use the net proceeds for purchasing gold bullion, working capital, and general corporate purposes.
🚩 Red Flags
- Significant dilution likely due to the issuance of over 3.8 million new shares.
- Unconventional use of proceeds (purchasing gold bullion) may indicate a shift in core business focus or a strategy to hedge against cash volatility.
📋 Key Facts
- Total shares issued: 3,852,149 common shares.
- Offering price: $3.90 per share.
- Gross proceeds: Approximately $15.02 million (before expenses).
- Underwriters: Clear Street LLC and Needham & Company, LLC.
- Lock-up period: 90 days for officers, directors, and certain stockholders.
- Use of proceeds includes purchasing gold bullion.
BioSig Technologies, Inc. has amended its July 2025 Debenture Purchase Agreement with Yorkville (YA II PN, LTD), significantly increasing the potential debt issuance to up to $100 million through multiple secured convertible debentures.
🚩 Red Flags
- Significant potential dilution due to large-scale convertible debentures (totaling up to $100M).
- The 'floor price' mechanism for conversions is highly favorable to the investor and can lead to massive share issuance if the stock price declines.
- High debt load relative to micro-cap scale ($100M in potential new secured debt).
📋 Key Facts
- Amendment dated August 13, 2025, with YA II PN, LTD (Yorkville).
- Structure includes a first secured convertible debenture of $25,000,000 and a second for $25,000,000.
- Potential for additional secured convertible debentures up to an aggregate principal amount of $50,000,000.
- Conversion floor price set at 20% of the Nasdaq Official Closing Price immediately prior to the original Debenture Purchase Agreement date.
BioSig Technologies, Inc. is amending its previous 8-K to provide supplemental disclosures regarding the acquisition of Streamex Exchange Corporation. The amendment includes risk factors, business overview, and pro forma financial statements for the combined entity.
🚩 Red Flags
- The filing explicitly notes the inclusion of 'Risk Factors' related to Streamex’s business and the consummation of the transaction, which typically implies significant integration or operational risks.
📋 Key Facts
- Acquisition target: Streamex Exchange Corporation (and related entities).
- Filing is an amendment (8-K/A) to a previously filed report from May 30, 2025.
- Includes audited financial statements for Streamex as of Dec 31, 2024, and unaudited condensed financial statements as of March 31, 2025.
- Provides unaudited pro forma combined balance sheet as of March 31, 2025, and statement of operations for the year ended Dec 31, 2024, and three months ended March 31, 2025.
BioSig Technologies entered into a massive $100 million secured convertible debenture purchase agreement with Yorkville (YA II PN, LTD.) and a simultaneous $1 billion standby equity purchase agreement (SEPA). The deal involves significant potential dilution through floor-price conversion mechanisms and requires a first-priority security interest in substantially all company assets.
🚩 Red Flags
- Extremely high potential dilution due to the $1B SEPA and convertible debentures with floor-price mechanisms.
- High interest rate penalty (18%) in the event of default.
- Lender has a first-priority security interest in substantially all company assets, including intellectual property.
- The conversion mechanism (97% of lowest VWAP) is highly dilutive and favors the investor in downward price movements.
📋 Key Facts
- Total Convertible Debenture amount: $100,000,000 ($75M First, $25M Second).
- Debentures carry 4.00% interest, increasing to 18.00% upon event of default.
- Conversion price is the lower of 125% of VWAP or 97% of the lowest daily VWAP over three days (subject to a 20% floor).
- The debt is secured by a first-priority security interest in substantially all existing and future assets, including Streamex Exchange Corporation.
- Simultaneous Standby Equity Purchase Agreement (SEPA) allows for up to $1,000,000,000 of common stock issuance over 36 months.
- The SEPA price is set at 97% of the lowest VWAP over three consecutive trading days.
BioSig Technologies, Inc. has completed a reverse merger/asset acquisition involving Streamex Exchange Corporation, resulting in a complete overhaul of the company's leadership and board composition. The transaction involves significant equity issuance to finders (3.75% of outstanding shares) and the establishment of new Special Voting Preferred Stock.
🚩 Red Flags
- Significant dilution: Issuance of 3.75% to finders plus massive issuance of exchangeable shares for the acquisition.
- Management overhaul: Complete replacement of the CEO and Chairman suggests a change in corporate direction/control.
- Large severance package: $400,000 payout to outgoing CEO Amato.
- Complex capital structure: Issuance of 'Special Voting Preferred Stock' and 'Exchangeable Shares' creates complex voting rights.
📋 Key Facts
- Consummated the acquisition of Streamex Exchange Corporation on May 28, 2025.
- The transaction involved the issuance of approximately 109 million exchangeable shares to Streamex shareholders.
- Three finders were engaged, receiving an aggregate of 3.75% of outstanding common stock as compensation.
- CEO Anthony Amato resigned; Henry McPhie (from Streamex) appointed as new CEO and Morgan Lekstrom (from Streamex) appointed as Chairman.
- The board was restructured to include two members designated by the incoming Streamex management.
- Former CEO Anthony Amato received a severance agreement totaling $400,000 payable over eight months.
BioSig Technologies, Inc. has entered into a definitive share purchase agreement to acquire Streamex Exchange Corporation via a complex exchange of shares and the creation of special voting preferred stock. The transaction involves a significant change in control, resulting in the resignation of the current CEO and a restructuring of the Board of Directors.
🚩 Red Flags
- Significant dilution: Existing shareholders will be diluted from 100% to approximately 25% of the company's fully diluted common stock.
- Change in control: The transaction effectively hands control of the company to the Streamex group.
- Complex voting structure: Use of 'Special Voting Preferred Stock' and a Trustee to manage voting rights is an unconventional and complex governance mechanism.
- Executive turnover: Resignation of the current CEO accompanied by a significant severance package ($400,000).
📋 Key Facts
- Acquisition of Streamex Exchange Corporation through an exchange of 109,070,079 exchangeable shares at a 2.05:1 ratio.
- Upon stockholder approval, Streamex shareholders will hold approximately 75% of fully diluted common stock, leaving existing BioSig stockholders with 25%.
- Creation of 'Special Voting Preferred Stock' to allow exchangeable shareholders to exercise voting rights through a Trustee.
- Current CEO Anthony Amato will resign; Henry McPhie (Streamex co-founder) will become the new CEO.
- Board restructuring: The board will expand to 6 members, with Streamex designating two members, including Chairman Morgan Lekstrom.
- Anthony Amato's resignation includes a $400,000 severance package and accelerated equity vesting.
BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company had previously received a deficiency notice but successfully maintained a closing price at or above the threshold for 10 consecutive business days.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirements (though currently resolved).
📋 Key Facts
- Nasdaq notified the Company on April 11, 2025, regarding failure to maintain a $1.00 minimum bid price.
- The company achieved compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days (April 30, 2025, to May 13, 2025).
- Nasdaq Staff has officially closed the matter regarding Listing Rule 5550(a)(2).
BioSig Technologies, Inc. has entered into a Letter of Intent (LOI) for a proposed merger with Streamex Exchange Corporation. The transaction is structured such that former Streamex stockholders would control approximately 75% of the combined company's equity.
🚩 Red Flags
- Significant dilution for existing BioSig shareholders (current shareholders retain only ~25% ownership).
- Transaction involves the issuance of Convertible Preferred Stock, which can lead to further future dilution.
- The merger is currently at the LOI stage and subject to significant closing conditions including due diligence.
📋 Key Facts
- Entered into a Letter of Intent (LOI) on May 5, 2025, with Streamex Exchange Corporation.
- Streamex is a Vancouver, British Columbia-based corporation.
- Post-merger structure: Former Streamex stockholders to own ~19.9% via Common Stock and the remainder via Convertible Preferred Stock, totaling ~75% of outstanding equity.
- The transaction is subject to due diligence, definitive documentation, and regulatory/Nasdaq approval.
BioSig Technologies, Inc. announced the resignation of its independent auditor, Marcum LLP, and the simultaneous engagement of CBIZ CPAs P.C. The filing notes that prior audits included explanatory paragraphs regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language present in recent audit reports.
- Material weaknesses identified in internal controls over financial reporting (ICFR).
- Auditor change occurring alongside existing material control deficiencies.
📋 Key Facts
- Marcum LLP resigned as the independent registered public accounting firm on April 30, 2025.
- CBIZ CPAs P.C. was engaged as the new independent auditor on April 30, 2025.
- Auditor reports for fiscal years ended Dec 31, 2024, and Dec 31, 2023, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Material weaknesses were identified in internal controls during the last two fiscal years (2023 and 2024) related to stock-based compensation, period-end financial disclosure reviews, and segregation of duties.
BioSig Technologies, Inc. issued 2,750,000 restricted shares of common stock to service providers on April 24, 2025, as compensation for business development services.
🚩 Red Flags
- Issuance of restricted shares to service providers can lead to future dilution upon registration/liquidation.
📋 Key Facts
- Date of event: April 24, 2025
- Total shares issued: 2,750,000 restricted shares of common stock
- Recipients: Certain service providers
- Consideration: Business development services
- Exemption used: Section 4(a)(2) of the Securities Act (unregistered sale)
BioSig Technologies, Inc. received a notice from Nasdaq stating the company is in violation of the minimum bid price requirement ($1.00 per share). The company has been granted a 180-day compliance period ending October 8, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Potential for mandatory reverse stock split to cure deficiency
- Failure to maintain minimum $1.00 bid price over a 30-day period indicates significant downward pressure on share price.
📋 Key Facts
- The deficiency was determined based on the closing bid price between February 27, 2025, and April 10, 2025.
- Compliance period ends October 8, 2025.
- To regain compliance, the stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
- The company may need to effect a reverse stock split to meet requirements if it cannot regain compliance through organic price appreciation.
BioSig Technologies, Inc. has successfully regained full compliance with Nasdaq listing requirements after meeting the Equity Rule threshold. This resolves previous delisting risks related to minimum stockholders' equity requirements.
🚩 Red Flags
- Historical delisting risk/non-compliance status (previously notified Oct 18, 2024).
📋 Key Facts
- On March 24, 2025, Nasdaq notified the Company that it has met qualifications to regain full compliance for continued listing on the Nasdaq Capital Market.
- The Company had been under a deadline of March 7, 2025, following an exception granted by the Nasdaq Listing and Hearing Review Council.
- Compliance was achieved via the 'Equity Rule' (alternative requirement of $2.5 million in stockholders' equity) rather than the market value rule ($35 million).
- The Company submitted evidence of compliance on March 6, 2025.
BioSig Technologies, Inc. reports that recent equity raises have likely brought its stockholders' equity above the $2.5 million requirement for Nasdaq compliance. The company is currently awaiting formal confirmation from Nasdaq regarding its status and remains under ongoing monitoring.
🚩 Red Flags
- Delisting risk: The company is operating under a temporary exception that expires March 7, 2025.
- Ongoing monitoring: Nasdaq will continue to monitor compliance; failure to meet equity requirements in the next periodic report could trigger delisting.
- Heavy reliance on dilutive financing (ATM and Subscription Agreements) to maintain listing status.
📋 Key Facts
- Nasdaq granted an exception to comply with Listing Rule 5550(b) through March 7, 2025.
- The company sold 5,172,321 shares for $4,847,497 between Jan 17, 2025, and March 5, 2025.
- Entered into an Equity Subscription Agreement with Lind Global Fund III, LP for up to $5.0 million in common stock over 36 months.
- Company believes stockholders' equity is now at least $2.5 million as of the filing date.
BioSig Technologies, Inc. entered into a Securities Purchase Agreement to sell 758,514 shares of common stock and warrants for approximately $819k. The company also provided an update on its ongoing At-The-Market (ATM) offering, noting significant proceeds raised since mid-January.
🚩 Red Flags
- Dilutive financing: The issuance of warrants and common stock will increase the total share count.
- ATM dependency: High volume of shares sold via ATM ($4M+) suggests a reliance on continuous equity dilution to fund operations.
📋 Key Facts
- Sold 758,514 shares at $1.07974 per share to accredited investors.
- Issued warrants for up to 758,514 shares at an exercise price of $0.95474 per share.
- Warrants become exercisable six months after issuance and expire in 3.5 years.
- Total consideration for the new securities: $818,997.91.
- ATM offering update: Sold 4,413,807 shares between Jan 17, 2025, and March 5, 2025, at an average price of $0.9127 per share.
- Total ATM proceeds to date: $4,028,498.73.
BioSig Technologies entered into an Equity Subscription Agreement with Lind Global Fund III, LP for a potential $5.0 million equity financing via periodic advances of common stock. The agreement includes a significant discount to market price and involves the issuance of commitment shares.
🚩 Red Flags
- Highly dilutive financing structure: The pricing mechanism (95% of VWAP) and the potential for 10,000,000 total shares to be issued represents significant dilution risk.
- Death Spiral characteristics: The ability to trigger advances at a discount to market price can create downward pressure on the stock price.
- Volume restrictions: Advances are capped at 66.667% of average daily volume, which may lead to prolonged selling pressure over time.
📋 Key Facts
- Entered into an Equity Subscription Agreement with Lind Global Fund III, LP on February 28, 2025.
- The Company has the right (but not obligation) to sell up to $5.0 million in common stock over 36 months.
- Shares will be priced at 95% of the lowest daily VWAP during a five-day period preceding the advance notice.
- Company is issuing 108,542 'Commitment Shares' as consideration for the investor's commitment.
- The agreement includes an Exchange Cap of 4,605,765 shares (19.99% of outstanding stock) unless specific conditions are met or shareholder approval is obtained.
BioSig Technologies, Inc. held its 2024 annual meeting where stockholders approved a proposal authorizing the Board to execute a reverse stock split at a ratio between 1-for-2 and 1-for-10. The meeting also resulted in the election of five directors and the ratification of Marcum LLP as auditors.
🚩 Red Flags
- Approval of a reverse stock split (1-for-2 to 1-for-10) is often used to combat delisting notices or low share prices.
- Significant increase in authorized shares under the Incentive Plan (3.5M additional shares) may lead to future dilution.
📋 Key Facts
- Stockholders approved a Reverse Stock Split Proposal with 8,666,835 votes 'For' and 918,208 'Against'.
- The reverse split ratio is to be determined by the Board within a range of 1-for-2 to 1-for-10.
- Stockholders approved an amendment to increase the total number of shares authorized under the Incentive Plan by 3,500,000 to a total of 4,376,595 shares.
- Five directors were elected: Anthony Amato, Frederick D. Hrkac, Christopher A. Baer, Donald F. Browne, and Steven E. Abelman.
- Marcum LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
BioSig Technologies, Inc. entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $8.5 million of common stock. The proceeds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to address immediate liquidity needs or cash burn issues.
📋 Key Facts
- Entered into Sales Agreement with H.C. Wainwright & Co., LLC on December 18, 2024.
- Aggregate offering amount: up to $8,500,000 of common stock.
- The offering is being conducted under a shelf registration statement (Form S-3) declared effective by the SEC on December 17, 2024.
- Agent (H.C. Wainwright & Co., LLC) will receive a 3% cash commission on gross sales.
- Proceeds are designated for working capital and general corporate purposes.
BioSig Technologies, Inc. announced that a Minnesota District Court has granted its motion to dismiss a lawsuit filed by Michael Gray Fleming. The lawsuit sought $288,000 in damages regarding alleged failure to issue restricted stock awards.
🚩 Red Flags
- None identified; this is a favorable legal outcome for the company.
📋 Key Facts
- The lawsuit was originally filed on March 22, 2024, in Hennepin County, Minnesota District Court.
- Plaintiff Michael Gray Fleming sought at least $288,000 in damages.
- Defendants included the Company and its former CEO and CFO.
- The court issued an Order Granting Motion to Dismiss on December 3, 2024.
BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company was previously notified of a deficiency but successfully maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
🚩 Red Flags
- Historical delisting risk: The company was recently in violation of Nasdaq's minimum bid price requirement.
📋 Key Facts
- Nasdaq Staff notified the company on October 24, 2024, regarding failure to maintain a minimum bid price of $1.00.
- The company achieved compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days (Oct 30, 2024 - Nov 12, 2024).
- Nasdaq has officially closed the matter regarding Listing Rule 5550(a)(2) compliance.
- The company issued a press release on November 13, 2024, to announce the regained compliance.
BioSig Technologies, Inc. received a deficiency notice from Nasdaq because its common stock failed to maintain the minimum $1.00 bid price requirement over a specified period ending October 23, 2024. The company has been granted a 180-day compliance period to regain compliance by achieving a $1.00 closing bid price for ten consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price).
- Explicit mention of potential requirement for a reverse stock split to maintain listing.
- Historical stock price performance has been insufficient to maintain the $1.00 threshold.
📋 Key Facts
- Received Nasdaq deficiency notice on October 24, 2024.
- Failure to meet the minimum $1.00 per share bid price requirement based on closing prices from June 11, 2024, through October 23, 2024.
- The company has a 180-calendar-day compliance period to regain compliance.
- Compliance can be achieved if the stock closes at $1.00 or higher for ten consecutive business days.
- If compliance is not met within the initial period, the company may need to effect a reverse stock split to meet listing requirements.
BioSig Technologies received a grace period from the Nasdaq Listing and Hearing Review Council to regain compliance with the Minimum Market Value of Listed Securities (MVLS) rule. The company must meet the $35 million market value requirement by March 7, 2025.
🚩 Red Flags
- Non-compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) rule.
- Requirement to reach a $35 million market cap by March 7, 2025, poses significant liquidity and valuation risk for a micro-cap company.
📋 Key Facts
- Nasdaq Listing and Hearing Review Council granted a grace period until March 7, 2025.
- The compliance requirement is Nasdaq Listing Rule 5550(b)(2) (MVLS Rule).
- The MVLS rule requires the market value of listed securities to be at least $35 million.
- Common stock will commence trading on The Nasdaq Stock Market effective October 23, 2024.
BioSig Technologies, Inc. has appointed its current CEO, Anthony Amato, as Chairman of the Board following the resignation of Kenneth L. Londoner. The filing also details a new executive employment agreement for Mr. Amato effective August 1, 2024.
🚩 Red Flags
- Significant equity compensation package (over 3.9 million total shares/options) for the CEO in a micro-cap context.
- Substantial severance provisions including double-trigger change of control protections and 18 months of health insurance coverage.
📋 Key Facts
- Anthony Amato (CEO) appointed as Chairman of the Board on September 11, 2024.
- Kenneth L. Londoner resigned as Chairman (previously announced February 27, 2024).
- New Executive Employment Agreement for Mr. Amato effective August 1, 2024.
- Annual base salary set at $300,000 with a 60% discretionary bonus eligibility.
- Grant of 2,400,000 stock options with an exercise price of $0.4479 per share.
- Grant of 275,000 fully vested restricted shares and 1,275,000 time-based restricted shares to Mr. Amato.
BioSig Technologies, Inc. has commenced trading on the OTCQB following a suspension of its Nasdaq listing. The company is currently appealing the Nasdaq delisting decision to the Listing and Hearing Review Council.
🚩 Red Flags
- Delisted from Nasdaq (primary exchange) as of June 12, 2024.
- Trading moved to OTCQB, which typically results in significantly lower liquidity and higher volatility for micro-cap stocks.
- Ongoing legal/regulatory uncertainty regarding the appeal process with the Nasdaq Listing and Hearing Review Council.
📋 Key Facts
- Commenced trading of common stock on the OTCQB (operated by OTC Markets Group, Inc.) on July 23, 2024.
- Nasdaq trading was suspended effective June 12, 2024, following a delisting decision on June 10, 2024.
- The company filed an appeal to the Nasdaq Listing and Hearing Review Council on July 10, 2024.
- Currently awaiting a decision regarding the appeal of the delisting.
BioSig Technologies, Inc. was notified that the Nasdaq Hearings Panel declined to reconsider its decision to delist the company's common stock. Trading on Nasdaq has been suspended as of June 12, 2024, and the company is currently appealing the decision to the Nasdaq Listing and Hearing Review Council.
🚩 Red Flags
- Delisting notice from a major exchange (Nasdaq).
- Trading suspension on primary exchange.
- Downgrade to OTC Pink tier reduces liquidity and institutional visibility.
📋 Key Facts
- Nasdaq Hearings Panel declined to reconsider the June 10, 2024 delisting decision on June 24, 2024.
- Trading of common stock was suspended on Nasdaq effective at the open of business on June 12, 2024.
- Securities are currently eligible to trade on the OTC Market's Pink Current Information tier.
- The company is seeking approval to trade on the OTCQB platform.
- On June 25, 2024, the company appealed the determination to the Nasdaq Listing and Hearing Review Council.
BioSig Technologies, Inc. has received formal notice from the Nasdaq Hearings Panel to delist its common stock due to failure to meet minimum stockholders' equity requirements. Trading on Nasdaq is scheduled to be suspended effective June 12, 2024.
🚩 Red Flags
- Delisting notice (Nasdaq)
- Failure to meet minimum stockholders' equity requirements
- Imminent suspension of trading on a major exchange (Nasdaq) moving to OTC Pink
- Uncertainty regarding the success of appeals or ability to satisfy Nasdaq conditions
📋 Key Facts
- Nasdaq Hearings Panel determined delisting due to non-compliance with Nasdaq Listing Rule 5550(b)(2) (minimum stockholders' equity).
- Trading on Nasdaq is scheduled for suspension effective at the open of business on Wednesday, June 12, 2024.
- Common stock is expected to move to OTC Markets 'Pink Current Information' tier under symbol 'BSGM' starting June 12, 2024.
- The Company intends to seek reconsideration from the Panel and appeal to the Nasdaq Listing and Hearing Review Council.
BioSig Technologies, Inc. announced the resignation of its acting CFO and principal accounting officer, Frederick D. Hrkac, effective June 5, 2024. The company has appointed Ferdinand Groenewald as interim CFO, principal accounting officer, and VP of Finance via a new consulting agreement.
🚩 Red Flags
- Sudden departure of the acting CFO/Principal Accounting Officer.
- Transition from an 'acting' officer to a 'consultant' rather than a full-time permanent hire may indicate ongoing financial instability or cost-cutting measures.
📋 Key Facts
- Frederick D. Hrkac resigned as acting CFO and principal accounting officer on June 5, 2024.
- Ferdinand Groenewald appointed as interim CFO, principal accounting officer, and VP of Finance effective June 5, 2024.
- Groenewald's compensation is set at a fixed rate of $15,000 per month plus expense reimbursement.
- The consulting agreement for Groenewald has no fixed end date and requires 30 days' notice for termination.
BioSig Technologies, Inc. completed a combined registered direct offering and private placement on May 30, 2024, raising approximately $3.0 million in gross proceeds. The offering included the issuance of common stock at $1.91 per share and warrants with an exercise price of $1.78 per share.
🚩 Red Flags
- Significant dilution potential from both common stock issuance and warrants (1:1 warrant coverage).
- Warrant exercise price ($1.78) is below the current offering price ($1.91), creating immediate downside pressure upon exercise.
- High cost of capital including 8% in fees to placement agent plus various expense reimbursements.
- Forward-looking statements explicitly mention risks regarding Nasdaq listing compliance and cash burn reduction targets.
📋 Key Facts
- Raised gross proceeds of approximately $3.0 million on May 30, 2024.
- Issued 1,570,683 shares of Common Stock at $1.91 per share via a registered direct offering.
- Issued Private Placement Warrants for up to 1,570,683 shares at an exercise price of $1.78 per share.
- H.C. Wainwright & Co., LLC acted as placement agent with an 8% total fee (7% cash, 1% management).
- Issued Agent Warrants for 109,948 shares at an exercise price of $2.3875 per share.
- The company is subject to a 60-day non-issuance restriction on new equity following the offering.
BioSig Technologies, Inc. received a decision from the Nasdaq Hearings Panel granting continued listing, contingent upon meeting specific compliance requirements by June 6, 2024.
🚩 Red Flags
- Delisting risk: The company is currently under scrutiny regarding listing requirements.
- Tight timeline: Compliance must be evidenced by June 6, 2024, providing a very narrow window for capital infusion or restructuring.
- Equity deficiency: The requirement to meet the $2.5 million stockholders' equity threshold suggests current equity levels are below this mandate.
📋 Key Facts
- The Nasdaq Hearings Panel granted a request for continued listing subject to conditions.
- The Company must comply with all applicable Nasdaq Capital Market criteria.
- A critical requirement is maintaining at least $2.5 million in stockholders' equity (Nasdaq Listing Rule 5550(b)(1)).
- The deadline for demonstrating compliance is June 6, 2024.
BioSig Technologies, Inc. announced the appointment of several independent directors to its various board committees effective May 20, 2024.
📋 Key Facts
- Steven E. Abelman appointed as chairman of the Audit Committee and member of Compensation and Nominating/Corporate Governance Committees.
- Donald F. Browne appointed as chairman of the Compensation and Nominating/Corporate Governance Committees and member of the Audit Committee.
- Chris Baer appointed as a member of the Audit, Compensation, and Nominating/Corporate Governance Committees.
- Directors will receive compensation consistent with market practices and the Company's non-employee director compensation policy.
BioSig Technologies has regained compliance with Nasdaq's minimum bid price requirement after trading above $1.00 for 20 consecutive days. However, the company remains non-compliant regarding market value of listed securities and board requirements, and a delisting hearing is still scheduled for May 7, 2024.
🚩 Red Flags
- Continued non-compliance with market value of listed securities requirement.
- Ongoing delisting risk despite regaining bid price compliance.
- Non-compliance with independent board and committee requirements.
- Company is ineligible for a second 180-day cure period due to failing the $5M minimum stockholders' equity requirement.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price requirement).
- Compliance achieved by closing at or above $1.00 per share for 20 consecutive business days from April 8, 2024, to May 3, 2024.
- Company remains non-compliant with Nasdaq market value of listed securities requirements.
- Company remains non-compliant with public shell and independent board/committee requirements.
- A hearing before the Nasdaq Hearings Panel is scheduled for May 7, 2024.
BioSig Technologies entered into a Securities Purchase Agreement on May 1, 2024, to raise capital through the sale of common stock and warrants. The transaction involves both new cash infusion and the conversion of an existing $500,000 promissory note.
🚩 Red Flags
- Significant portion of financing ($509k) is a debt conversion rather than new cash, indicating the company is servicing existing obligations by issuing equity.
- The use of warrants with an exercise price below current issuance price suggests potential future dilution.
📋 Key Facts
- Total consideration: $1,144,164.46
- Cash component: $634,999.11
- Debt conversion component: $509,165.35 (principal and accrued interest from a 12% Note due 2026)
- Shares issued: 783,406 shares of common stock at $1.4605 per share
- Warrants issued: Up to 391,703 warrants with an exercise price of $1.398 per share
- Warrant terms: Exercisable six months after issuance; expires 5.5 years from issuance
BioSig Technologies, Inc. announced the appointment of three new independent directors to its Board: Steven E. Abelman, Donald F. Browne, and Chris Baer. This move results in a fully constituted Board of Directors.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Appointed Steven E. Abelman as an independent director on May 3, 2024; expert in commercial litigation and bankruptcy law.
- Appointed Donald F. Browne, C.P.A., as an independent director on May 3, 2024; specialist in business accounting and tax reporting.
- Confirmed the appointment of Chris Baer as a director (previously announced on May 2, 2024).
- All three new appointees qualify as independent directors under NASDAQ Listing Rules.
- The appointments are for terms expiring at the next annual meeting or until successors are elected.
BioSig Technologies, Inc. announced a leadership transition effective April 30, 2024, appointing Anthony Amato as President and CEO. Concurrently, Mr. Hrkac resigned from his role as President and Principal Executive Officer but will remain on the Board and serve as acting CFO.
🚩 Red Flags
- Management instability: Simultaneous departure of the President/CEO and appointment of an acting CFO suggests potential internal reorganization or volatility.
- The CEO is moving from a consultant/advisory role directly to the top executive position, which can sometimes indicate rapid shifts in company direction.
📋 Key Facts
- Anthony Amato appointed as Director, President, CEO, and Principal Executive Officer effective April 30, 2024.
- Mr. Hrkac resigned as President and Principal Executive Officer effective April 30, 2024.
- Mr. Hrkac will continue to serve as a director and acting Chief Financial Officer (CFO).
- Anthony Amato previously served on the advisory board from January 2021 to February 2024 and as a consultant since March 2024.
BioSig Technologies, Inc. announced the appointment of Chris Baer to its Board of Directors on May 2, 2024. Mr. Baer brings extensive commercial experience in the medical device and electrophysiology sectors.
📋 Key Facts
- Appointment date: May 2, 2024
- Appointee: Chris Baer (Age 55)
- Role: Director and member of Audit, Nominating, and Compensation committees
- Professional Background: Currently Chief Commercial Officer at CDL Nuclear Technologies; formerly VP of Commercial Operations at Impulse Dynamics and leadership roles at St. Jude Medical / Abbott.
- Term: Until the next annual meeting or until successor is elected/qualified.
BioSig Technologies is facing imminent delisting from the Nasdaq Capital Market after being designated a 'public shell' by Nasdaq Staff. The company has appealed the determination and has a hearing scheduled for May 7, 2024.
🚩 Red Flags
- Designation as a 'public shell' by Nasdaq Staff
- Extreme loss of human capital (only 1 employee remains)
- Massive board and management exodus
- Failure to meet minimum bid price and stockholders' equity requirements
- Imminent delisting threat
📋 Key Facts
- Nasdaq Staff believes the Company no longer has an operating business and is a 'public shell'.
- The Company failed to meet the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- The Company does not comply with the $5,000,000 minimum stockholders' equity requirement.
- Significant workforce reduction occurred on Feb 5, 2024, including the COO and CCO.
- Major leadership turnover: CFO resigned; CEO Kenneth Londoner resigned; 6 of 7 directors resigned.
- As of the filing, the Company has only one employee and one board member remaining.
- Nasdaq hearing scheduled for May 7, 2024.
BioSig Technologies, Inc. issued a $500,000 promissory note to an investor on March 7, 2024. The note carries a 12% annual interest rate and is due in full on March 7, 2026.
🚩 Red Flags
- Debt issuance for a relatively small amount ($500k) often indicates immediate liquidity needs or working capital requirements in micro-cap companies.
- High interest rate (12%) suggests the company may be facing higher risk profiles from lenders.
📋 Key Facts
- Issued a Promissory Note for $500,000 principal amount.
- Interest rate is 12% per annum, payable in cash.
- Maturity date is March 7, 2026.
- The note was issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
BioSig Technologies, Inc. has received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement and failing to meet the $5,000,000 minimum stockholders' equity requirement. The company has filed an appeal to request a hearing before the Nasdaq Hearings Panel.
🚩 Red Flags
- Delisting notice received from Nasdaq
- Failure to meet minimum stockholders' equity requirement ($5M)
- Ineligibility for a second compliance period
- Ongoing uncertainty regarding ability to maintain exchange listing
📋 Key Facts
- Nasdaq issued a delisting notice on March 5, 2024, after the company failed to regain compliance with Rule 5810(c)(3)(A).
- The company failed both the minimum bid price requirement ($1.00) and the $5,000,000 minimum stockholders' equity initial listing requirement.
- The company is ineligible for a second 180-day compliance period under Rule 5810(c)(3)(A)(2).
- On March 11, 2024, the company submitted a request for a hearing before the Nasdaq Hearings Panel to appeal the determination.
- The stock continues to trade on the Nasdaq Capital Market under symbol 'BSGM' pending the outcome of the appeal.
BioSig Technologies, Inc. announced a significant leadership transition effective February 27, 2024. Kenneth L. Londoner resigned from all roles including CEO and Executive Chairman, while Frederick D. Hrkac was appointed as Director, President, and Principal Executive Officer.
🚩 Red Flags
- Sudden departure of the CEO and Executive Chairman simultaneously.
- Leadership vacuum created by a single individual (Hrkac) assuming multiple top-tier roles (Director, President, and PEO).
📋 Key Facts
- Kenneth L. Londoner resigned as Director, Executive Chairman, and CEO effective February 27, 2024.
- Frederick D. Hrkac appointed as Director, President, and Principal Executive Officer effective February 27, 2024.
- The company stated Mr. Londoner's resignation was not due to any disagreement regarding operations, policies, or practices.
BioSig Technologies, Inc. experienced a massive leadership exodus involving the resignation of its CFO and six members of the Board of Directors within a single week in February 2024.
🚩 Red Flags
- Massive board turnover: 6 directors resigning simultaneously is highly unusual for a stable micro-cap.
- CFO departure: Loss of key financial leadership often precedes reporting delays or internal control issues.
- Multiple items in a single filing (Item 5.02): Indicates a period of significant organizational instability.
📋 Key Facts
- CFO Steve Buhaly resigned effective February 15, 2024.
- Four directors (David Weild IV, Donald E. Foley, Patrick J. Gallagher, and James J. Barry) resigned effective February 19, 2024.
- Two additional directors (James L. Klein and Frederick D. Hrkac) resigned effective February 20, 2024.
- The company stated that none of the resignations were due to disagreements regarding operations, policies, or practices.
BioSig Technologies, Inc. issued a press release announcing that physicians have completed over 100 cases utilizing the company's Near Field Tracking algorithm. This filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute material non-public information.
📋 Key Facts
- Physicians have completed over 100 cases using the Near Field Tracking algorithm as of February 6, 2024.
- The announcement was made via a press release attached as Exhibit 99.1.
- The filing is provided under Item 7.01 to satisfy Regulation FD requirements.
BioSig Technologies, Inc. (BSGM) has announced a significant workforce reduction involving 16 employees, including the COO and CCO, to reduce annual cash burn by approximately 50%. The filing is an amendment to correct previous errors regarding unexecuted consulting agreements.
🚩 Red Flags
- Significant reduction in force (16 employees) including key C-suite executives.
- High cost of restructuring ($713,924) relative to micro-cap scale.
- Heavy use of equity for retention bonuses ($578,636), indicating potential dilution and cash constraints.
- Correction of previous filing (Amendment 1/A) regarding unexecuted agreements suggests internal control or communication issues.
📋 Key Facts
- Workforce reduction of 16 employees completed as of January 31, 2024.
- Departure of Chief Operating Officer (John Sieckhaus) and Chief Commercial Officer (Gray Fleming).
- Estimated total aggregate costs for the reduction: ~$713,924.
- Breakdown of costs includes $135,288 in severance/departure fees and $578,636 in retention bonuses paid in equity.
- The company aims to reduce annual cash burn by approximately 50%.
- Amendment filed to correct the Original Form 8-K regarding unexecuted consulting agreements.
BioSig Technologies, Inc. has executed a significant workforce reduction involving 16 employees to reduce annual cash burn by approximately 50%. The restructuring includes the departure of both the Chief Operating Officer and the Chief Commercial Officer.
🚩 Red Flags
- Significant reduction in workforce (16 employees) to address cash burn issues.
- Departure of two key C-suite executives (COO and CCO).
- High proportion of restructuring costs being paid in equity rather than cash, which may indicate liquidity constraints.
- Risk factor warning regarding potential litigation from employee terminations.
📋 Key Facts
- Workforce reduction involves the departure of 16 employees effective January 31, 2024.
- The reduction aims to decrease annual cash burn by approximately 50%.
- Chief Operating Officer John Sieckhaus and Chief Commercial Officer Gray Fleming are departing their executive roles.
- Total estimated aggregate costs for the reduction are approximately $919,249.
- Estimated costs include $578,636 in retention bonuses and $205,325 in consulting services, primarily paid in equity.
- Departing executives will remain as consultants: Fleming ($138,667 in equity over 4 months) and Sieckhaus ($48,533 in equity over 2 months).
BioSig Technologies, Inc. has implemented a 1-for-10 reverse stock split to consolidate its common stock. The split is effective as of February 1, 2024, and the adjusted shares will begin trading on the Nasdaq Capital Market on February 2, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing).
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date/time: February 1, 2024, at 4:05 p.m. ET.
- Impact on shares outstanding: Reduction from approximately 93,344,435 shares to approximately 9,334,636 shares.
- New CUSIP number: 09073N300.
- Trading symbol remains 'BSGM' on the Nasdaq Capital Market.
- Fractional shares will be rounded up to the next whole number; no fractional shares issued.
BioSig Technologies, Inc. announced a workforce reduction via a press release on January 30, 2024. The filing is submitted under Item 7.01 to provide Regulation FD disclosure regarding the announcement.
🚩 Red Flags
- Workforce reduction often indicates cost-cutting measures due to liquidity constraints or declining revenue in micro-cap biotech firms.
📋 Key Facts
- The company issued a press release announcing a workforce reduction on January 30, 2024.
- The information was furnished under Item 7.01 rather than filed, limiting liability under Section 18 of the Exchange Act.
- Executive Chairman Kenneth L. Londoner signed the report.
BioSig Technologies, Inc. entered into a Securities Purchase Agreement to sell 2,607,170 shares of common stock and warrants to accredited/institutional investors for gross proceeds of $1,040,000.11.
🚩 Red Flags
- Significant dilution: Issuance of over 2.6 million shares plus warrants for a relatively small capital raise.
- Warrant exercise price ($0.3364) is below the current share purchase price ($0.3989), indicating potential downward pressure upon exercise.
- Small-cap financing: The total proceeds of ~$1M are minimal, suggesting the company may be facing liquidity constraints requiring frequent small-scale dilutive raises.
📋 Key Facts
- Date of agreement: January 12, 2024
- Total shares sold: 2,607,170 common stock shares
- Warrants issued: Warrants to purchase up to 1,303,585 shares of Common Stock
- Share purchase price: $0.3989 per share
- Warrant exercise price: $0.3364 per share
- Gross proceeds: $1,040,000.11
- Warrants become exercisable six months after issuance and expire in 5.5 years
- Offering conducted under Section 4(a)(2) and Regulation D (Rule 506)
BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum Market Value of Listed Securities (MVLS) requirement. The company successfully met the $35 million MVLS threshold for 10 consecutive business days ending January 4, 2024.
🚩 Red Flags
- Historical delisting risk due to failure to meet minimum Market Value of Listed Securities (MVLS) requirements.
📋 Key Facts
- The Company was previously notified on December 19, 2023, that it failed to meet the minimum MVLS of $35,000,000 required for Nasdaq Capital Market listing.
- A compliance period was granted until June 17, 2024.
- As of January 5, 2024, the Company's MVLS remained at or above $35,000,000 for 10 consecutive business days (Dec 20, 2023 – Jan 4, 2024).
- Nasdaq has confirmed that the compliance matter is now closed.